Get the Stockscreener App
13.15
0.49%
-0.105
Korro Bio Inc stock is traded at $13.15, with a volume of 25,118.
It is down -0.49% in the last 24 hours and up +25.67% over the past month.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
See More
Previous Close:
$13.26
Open:
$13.13
24h Volume:
25,118
Relative Volume:
0.13
Market Cap:
$193.72M
Revenue:
$6.39M
Net Income/Loss:
$-117.26M
P/E Ratio:
-1.054
EPS:
-12.4807
Net Cash Flow:
$-79.08M
1W Performance:
+0.11%
1M Performance:
+25.67%
6M Performance:
+8.78%
1Y Performance:
-44.25%
1-Day Range:
$12.80
$13.55
1-Week Range:
$12.66
$13.98
52-Week Range:
$5.2044
$55.89
Korro Bio Inc Stock (KRRO) Company Profile
Name
Korro Bio Inc
Sector
Industry
Phone
617-468-1999
Address
60 FIRST STREET, CAMBRIDGE
Compare KRRO vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
13.15 | 190.84M | 6.39M | -117.26M | -79.08M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
541.86 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
790.45 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,030.44 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.57 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
206.79 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-26 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-17-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-29-26 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-29-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-29-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-28-26 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jan-28-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-13-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-13-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-13-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-13-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-13-25 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Nov-13-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-16-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Raymond James | Strong Buy |
| Aug-14-24 | Initiated | William Blair | Outperform |
| Mar-28-24 | Reiterated | H.C. Wainwright | Buy |
| Feb-27-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-04-23 | Initiated | H.C. Wainwright | Buy |
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-10-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-13-23 | Downgrade | Cowen | Outperform → Market Perform |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jan-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-28-19 | Initiated | Cowen | Outperform |
| Oct-28-19 | Initiated | Goldman | Buy |
| Oct-28-19 | Initiated | JP Morgan | Overweight |
View All
Korro Bio Inc Stock (KRRO) Latest News
Korro Bio (NASDAQ:KRRO) Director Sells $398,552.00 in Stock - MarketBeat
Korro Bio (KRRO) director-tied funds sell 28K shares on Aug. 19 - Stock Titan
Balyasny Asset Management L.P. Reduces Stake in Korro Bio Inc (K - GuruFocus
Korro Bio Moves KRRO-121 Into First Human Trials, Raising the Stakes in Rare Disease RNA Editing - TipRanks
Korro Bio (NASDAQ:KRRO) Receives "Buy" Rating from HC Wainwright - MarketBeat
Form 8K Korro Bio Inc For: 19 August By Investing.com - Investing.com Nigeria
Korro Bio Advances KRRO-121 Into First Human Trial - TipRanks
Korro Bio, Inc. Announces Submission To Australian Alfred Health Human Ethics Committee To Initiate First-In-Human Phase 1/2 Clinical Trial For KRRO-121 - marketscreener.com
Korro (KRRO) Quarter in Focus: The Bottom-Line Figure Outpaces Its Comparison in the Latest Reading - vinanet.vn
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
KRRO Q2 2026 Earnings: Wider-Than-Expected Loss Avoided as Cost Discipline Drives 27.65% EPS BeatEarnings Yield Analysis - vinanet.vn
Insider Selling: Korro Bio (NASDAQ:KRRO) Director Sells $29,916.28 in Stock - MarketBeat
Korro Bio director Jean Francois Formela sells $29,916 in shares By Investing.com - Investing.com Australia
Korro Bio director Jean Francois Formela sells $29,916 in shares - Investing.com
Korro Bio (KRRO) director-affiliated funds sell 2,143 shares under 10b5-1 plan - Stock Titan
Korro Bio (NASDAQ:KRRO) Major Shareholder Acquires $19,283.78 in Stock - MarketBeat
Lynx1 Capital, Korro Bio 10% owner, buys $78,809 in stock - Investing.com
Lynx1 Capital, Korro Bio 10% owner, buys $78,809 in stock By Investing.com - Investing.com Canada
Korro Bio (KRRO) holder Lynx1 Capital reports 6,684-share indirect stock purchase - Stock Titan
Lynx1 Capital Management Lp Buys 5,222 Shares of Korro Bio (NASDAQ:KRRO) Stock - MarketBeat
HC Wainwright Has Strong Estimate for Korro Bio Q3 Earnings - marketbeat.com
All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy - Yahoo Finance
A US$42m Market Cap Boost Pleasing ToKorro Bio Insiders - webull.com
Analysts Offer Insights on Healthcare Companies: Corbus Pharmaceuticals (CRBP) and Korro Bio (KRRO) - theglobeandmail.com
Korro Bio (NASDAQ:KRRO) Releases Quarterly Earnings Results, Beats Expectations By $0.22 EPS - marketbeat.com
Korro Bio (NASDAQ:KRRO) Upgraded at Wall Street Zen - MarketBeat
H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Cantor Fitzgerald Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Korro Bio, Inc. expected to post a loss of $1.43 a shareEarnings Preview - TradingView
William Blair Maintains Korro Bio(KRRO.US) With Buy Rating - Moomoo
Raymond James reiterates Korro Bio stock rating on hyperammonemia outlook - Investing.com UK
Korro Bio Refines Capital Structure with Exchange Agreement - The Globe and Mail
Chardan Capital Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Korro Bio earnings beat by $0.24, revenue topped estimates - Investing.com Canada
Korro Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Korro Bio Reports $18.9 Million Q2 Net Loss - Quiver Quantitative
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Korro Bio Swaps 1.0M Shares for Pre-Funded Warrants to Venrock at $0.001 Exercise Price - TradingView
Korro Bio, Inc. Q2 2026: Revenue $0M, Net loss $(18.9)M, EPS $(1.07) — 10-Q Summary - TradingView
Korro Bio CEO Highlights Strategic Payoff, Advancing New Therapies - Intellectia AI
Korro Bio (KRRO) CEO sells 5,802 shares of stock to cover taxes - Stock Titan
Korro Bio Inc. (KRRO) Gains 1.23%: Trading Between $10.92 Support and $12.06 ResistanceMerger Arbitrage - vinanet.vn
Korro Bio (KRRO) Expected to Post Earnings on Tuesday - MarketBeat
Korro Bio (KRRO) Climbs 5.68% to $11.35 as RNA Editing Play Draws Fresh Buyer InterestFund Manager Survey - dars.gov.et
KRRO Q1 2026 Earnings: Narrower-than-Expected Loss Beats Estimates as Shares Slip 0.77%Post-Earnings Drift - vinanet.vn
KRRO Q1 2026 Earnings: Narrower-than-Expected Loss Signals Disciplined SpendingManagement Guidance Update - vinanet.vn
ADAR1 Capital Management LLC Takes Position in Korro Bio, Inc. $KRRO - MarketBeat
Korro Bio Inc (KRRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
KRRO|Korro Bio Inc|Price:10.370|Chg%:-0.080 - TradingKey
Korro Bio Inc (KRRO) Institutional Confidence - TradingKey
Korro Bio Inc (KRRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Korro Bio Inc Stock (KRRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.14%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):